Vergara Ruben, Vignini Elisa, Ciabatti Michele, Migliorini Angela, Valenti Renato, Antoniucci David
Division of Cardiology, Careggi-Hospital, Florence, Italy.
Division of Cardiology, Careggi-Hospital, Florence, Italy.
Cardiovasc Revasc Med. 2021 Jan;22:10-15. doi: 10.1016/j.carrev.2020.06.021. Epub 2020 Jun 18.
We sought to determine whether, in a real word context of patients with Acute Myocardial Infarction (AMI), multivessel disease (MVD) and cardiogenic shock (CS), the successful treatment with primary percutaneous coronary intervention (p-PCI) of only culprit lesions (OC-PCI) is associated with better long-term mortality rates than multivessel PCI (MV-PCI) of all significant lesions.
From our registry of all consecutive patients admitted for AMI between January 1995 and December 2016 we selected those presenting with CS and MVD successfully treated with p-PCI, and compared those who underwent OC-PCI against MV-PCI, either during the p-PCI (MV-pPCI) or by staged revascularization (Staged-PCI) during hospitalization. The primary endpoint was 2-year all-cause death.
Among 4210 patients with AMI, 406 (9.6%) presented CS (Killip class IV). A total of 292 patients had MVD. Of them, 252 (86.3%) were successfully treated with p-PCI, 159 patients with OC-PCI and 93 with MV-PCI, either in the same (n = 29) or staged procedure (n = 64). At 2-year follow-up the overall mortality was 47.6%, lower in MV-PCI group (37.6% vs 53.5% in OC-PCI, p = 0.019). Diabetes (HR = 1.50, 1.01-2.22), three vessel disease (HR = 1.49, 1.02-2.17) and basal left ventricular ejection fraction <15% (HR = 3.39, 2.41-6.27) were independent predictors of mortality, while MV-PCI was the only variable associated with improved survival (HR = 0.54, 0.36-0.81).
In this real world registry of AMI patients with MVD presenting CS, MV-PCI was associated with better long-term survival.
我们试图确定,在急性心肌梗死(AMI)、多支血管病变(MVD)和心源性休克(CS)患者的实际临床情况下,仅对罪犯病变进行直接经皮冠状动脉介入治疗(p-PCI,即OC-PCI)与对所有显著病变进行多支血管PCI(MV-PCI)相比,长期死亡率是否更低。
从我们1995年1月至2016年12月收治的所有连续AMI患者登记册中,我们选择了那些成功接受p-PCI治疗的CS和MVD患者,并比较了在p-PCI期间(MV-pPCI)或住院期间分期血运重建(分期PCI)接受OC-PCI与MV-PCI治疗的患者。主要终点是2年全因死亡。
在4210例AMI患者中,406例(9.6%)出现CS(Killip分级IV级)。共有292例患者存在MVD。其中,252例(86.3%)成功接受了p-PCI治疗,159例接受OC-PCI治疗,93例接受MV-PCI治疗,其中同期治疗(n = 29)或分期治疗(n = 64)。在2年随访时,总体死亡率为47.6%,MV-PCI组较低(37.6% vs OC-PCI组的53.5%,p = 0.019)。糖尿病(HR = 1.50,1.01 - 2.22)、三支血管病变(HR = 1.49,1.02 - 2.17)和基础左心室射血分数<15%(HR = 3.39,2.41 - 6.27)是死亡率的独立预测因素,而MV-PCI是与生存改善相关的唯一变量(HR = 0.54,0.36 - 0.81)。
在这个存在CS的MVD的AMI患者真实世界登记研究中,MV-PCI与更好的长期生存相关。